Oral semaglutide cuts major heart risks in people with type 2 diabetes by 14%, offering a powerful pill-based option. Both ...

A Kentucky doctor faces up to three years in prison after admitting he sold patients a non-approved weight-loss drug. Matthew ...

Several Ohio medical spas including two in the Mahoning Valley were sent letters by the Ohio Attorney General's Office ...

HealthDay News — The rate of emergency department visits for adverse events among patients dispensed semaglutide is low, with most visits involving gastrointestinal effects, according to a research ...

Ophthalmology Times - ophthalmology news, articles, and events in a timely and accurate manner for members of the ophthalmic ...

The Ohio attorney general's office issues warning letters to more than a dozen medical spas across the state for misleading claims about compounded versions of Ozempic, Wegovy and Mounjaro.

A Kentucky physician is facing up to three years in prison after distributing non-FDA approved semaglutide drugs, prosecutors ...

The FDA and the manufacturer of Ozempic, Novo Nordisk are urging patients, doctors and pharmacies to check their Ozempic ...

Semaglutide is an injectable medication that treats type 2 diabetes and obesity by regulating blood sugar levels. A ...

With Semaglutide, postmenopausal women can achieve significant weight loss, improve insulin sensitivity, and lower the risk ...

Researchers from the University of Bern analyzed over 300,000 FDA reports and found semaglutide use was linked to a higher ...

Glucagon-like peptide 1 receptor agonist therapy over a 12-month period is safe and effective in treating weight regain ...